{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:43:14Z","timestamp":1774532594478,"version":"3.50.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The clinical value of 16\u03b1-<jats:sup>18<\/jats:sup>F-fluoro-17 \u03b2-estradiol (<jats:sup>18<\/jats:sup>F-FES) PET in breast cancer has been widely investigated because it can visualize estrogen receptor\u2013expressing lesions. This relatively new radiotracer adds clinical values by characterization of metastasis in double primary cancer. It also has advantage in finding small brain lesions, which has no background brain activity. Here, we present <jats:sup>18<\/jats:sup>F-FES PET findings of brain and leptomeningeal metastases in a patient with breast and lung malignancy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004197","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T14:12:39Z","timestamp":1649167959000},"page":"e554-e556","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["18F-FES PET\/CT for Characterization of Brain and Leptomeningeal Metastasis in Double Primary Cancer Patient"],"prefix":"10.1097","volume":"47","author":[{"given":"Yeongjoo","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ie Ryung","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunggyun","family":"Ha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2967\/jnumed.120.256826","article-title":"Value of 18F-FES PET in solving clinical dilemmas in breast cancer patients: a retrospective study","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"e165","DOI":"10.1097\/RLU.0000000000003382","article-title":"Detection of dural metastases before the onset of clinical symptoms by 16\u03b1-[18F]Fluoro-17\u03b2-estradiol PET in a patient with estrogen receptor-positive breast cancer","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S1470-2045(18)30936-7","article-title":"Diagnostic accuracy and safety of 16\u03b1-[18F]fluoro-17\u03b2-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1634\/theoncologist.2019-0967","article-title":"Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16\u03b1-18F-Fluoro-17\u03b2-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications","volume":"25","year":"2020","journal-title":"Oncologist"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.2967\/jnumed.117.193649","article-title":"Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11307-013-0699-7","article-title":"A phase 2 study of 16alpha-[18F]-fluoro-17beta-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC)","volume":"16","year":"2014","journal-title":"Mol Imaging Biol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"6584","DOI":"10.1038\/s41598-017-06903-8","article-title":"A preliminary study of 18F-FES PET\/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel","volume":"7","year":"2017","journal-title":"Sci Rep"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.112.113373","article-title":"Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer","volume":"54","year":"2013","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:01:24Z","timestamp":1750536084000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004197","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,4]]}}}